US REGULATION & MARKET ACCESS

US State PMTA Directory Wars 2026: The Fragmented Legal Maze Every Vape Distributor Must Navigate

State-level PMTA directory laws are reshaping which vape products can legally reach retail shelves across the US

The US vape market has quietly entered its most complex regulatory chapter yet. While FDA enforcement grabs headlines, a quieter revolution is unfolding at the state level: PMTA directory laws are multiplying across the country, creating a patchwork of product eligibility rules that determine what can legally sit on retail shelves. For distributors, the game has shifted from chasing market share to fighting for market access.

The Rise of State-Level Product Gatekeeping

Federal PMTA enforcement has been slow. As of mid-2026, only about 45 ENDS products carry full FDA marketing authorization. But thousands of products remain on shelves through various legal grey areas — timely-filed PMTAs under review, stayed denial orders, or simply products the FDA hasn’t gotten around to addressing yet. States have stepped into this vacuum with their own answer: product directories.

The logic is straightforward. If the federal government can’t decide which products are legal, states will make the decision themselves. A PMTA directory law essentially creates a state-approved whitelist. Products on the list can be sold. Products off it cannot. No explicit flavor ban required. No product-category restriction needed. Just a list — and if your brand isn’t on it, you’re done.

The scale has grown fast. Industry compliance trackers count at least 15 states with active or enacted directory-style systems as of August 2026, including North Carolina, Wisconsin, Florida, West Virginia, South Carolina, Hawaii, Indiana, and now Pennsylvania. Several more — including Texas, Ohio, and Michigan — are in various stages of legislative review.

Pennsylvania Act 57: A Case Study in State-Level Market Architecture

Pennsylvania’s implementation offers the clearest window into how these directories actually work. Act 57 of 2025, now fully effective, requires every manufacturer of electronic cigarettes containing nicotine sold in the Commonwealth to be certified by the Attorney General’s office. The AG maintains a publicly accessible directory listing manufacturers, brand names, product categories, product names, and flavors.

The enforcement deadline is October 2026. After that date, only products on the directory can legally reach retail. The AG’s office has seizure authority and can recover costs from illegal actors — real teeth behind the regulation.

What the Pending List Reveals

When Pennsylvania updated its ENDS Pending Certifications list on June 26, the competitive landscape that emerged looked nothing like today’s retail shelf. The list covered 22 manufacturers, 42 brand families, and more than 600 SKUs across closed-pod systems, open-system e-liquids, and disposable vapes.

Three patterns jump out. First, tobacco majors dominate closed-pod systems — Vuse, JUUL, Logic, blu, NJOY have the PMTA submissions and legal resources to secure certification. Second, Chinese-linked disposable brands are entering the same certification process as Big Tobacco, not sidestepping it. OXBAR (through Hong Kong-registered YME Technology) and LYCO (through Shenzhen IVPS) are both seeking inclusion, suggesting these brands see state directories as the future reality rather than a temporary hurdle. Third, Smoore appears as OEM manufacturer for JT’s Logic brand, illustrating how Chinese manufacturing remains embedded in even the most regulated supply chains.

Products not on a state’s PMTA directory cannot legally be sold at retail after enforcement deadlines pass

Indiana’s Foreign-Made Vape Ban: The Country-of-Origin Wildcard

Indiana went further than any other state in 2026. Its new law prohibits the sale of vaping products manufactured in designated foreign adversaries — a category that, in practice, targets Chinese-manufactured disposables. The law took effect in mid-2026 and has already forced retailers to audit store inventories and overhaul supply chains.

Indiana’s approach sits outside the PMTA directory framework entirely. It doesn’t ask whether a product has FDA authorization. It asks where the product was made. For the dozens of US vape brands that rely on Shenzhen-based OEM manufacturing — even brands with PMTA submissions in progress — this creates a completely different compliance challenge.

The practical impact ripples through distribution. A brand manufactured in Shenzhen that secures its PMTA authorization and appears on a state directory may still be unsellable in Indiana. Compliance requires tracking not just regulatory status but country-of-origin data for every SKU in the portfolio.

Beyond PA and Indiana: The Broader Directory Landscape

Pennsylvania and Indiana represent two distinct regulatory philosophies — product-eligibility lists versus origin-based restrictions — but the broader trend spans the full spectrum.

Notice the divergence. Hawaii demands full FDA marketing authorization — the strictest standard anywhere. North Carolina accepts products with timely-filed PMTAs still under review. West Virginia layers directory requirements on top of shop licensing. Indiana ignores PMTA status entirely and focuses on manufacturing origin. Each state has built its own architecture, and none of them talk to each other.

Nicotine Pouch Gatekeeping: FDA Authorizes 30 Products, Two Companies Control Them All

While the directory wars rage across vape products, the nicotine pouch market is experiencing its own form of regulatory concentration. On August 4, 2026, the FDA authorized four additional on! nicotine pouch products — Rich Berry 2mg, Cappuccino 2mg, Cappuccino 4mg, and Autumn Spice 2mg — bringing the total number of FDA-authorized nicotine pouches to 30.

The authorizations came through the FDA’s nicotine pouch pilot program, which has now shifted from testing new review processes to applying those lessons across all nicotine pouch PMTA reviews. The pilot demonstrated that accelerated scientific review is possible — a signal that more authorizations may come faster than the vape category experienced.

But here’s the catch for distributors: every single one of those 30 authorized pouches comes from just two companies. Swedish Match USA (a PMI subsidiary) holds 20 ZYN authorizations. Helix Innovations (an Altria subsidiary) holds 10 on! authorizations. No independent brand, no Chinese manufacturer, no third-party player has received a single nicotine pouch marketing order.

For the oral nicotine segment, the FDA pathway has become a two-gate system. If you’re not PMI or Altria, you don’t have a legal product. The American Heart Association has criticized the authorization of flavored pouches, arguing it threatens youth nicotine initiation. Meanwhile, the regulatory pathway remains technically open to others — but the compliance resources, scientific data requirements, and timeline advantages held by the two incumbents create a structural moat that will take years to breach.

FDA PMTA review requires extensive scientific data — a barrier that concentrates authorized products among well-capitalized incumbents

What This Means for US Distributors

The convergence of state directory proliferation, country-of-origin restrictions, and concentrated nicotine pouch authorization creates a fundamentally different distribution landscape than even twelve months ago. The playbook has changed.

Five Actions for H2 2026

The Bigger Picture: Regulation as Market Architecture

What’s emerging in the US isn’t a single national regulatory model. It’s a collection of state-level market architectures — each state defining independently which products can reach consumers, under what conditions, and through what certification processes. The practical effect is that the range of legally available vapor products differs substantially between neighboring states.

For manufacturers and distributors, compliance is becoming a barrier to market access that favors companies with the resources to manage complex state-by-state certification, documentation, and inventory management. For consumers, the question of what’s available increasingly depends on which side of a state line they stand on.

The FDA’s own PMTA pipeline continues to move slowly — the MTO submission window has been pushed to late Q1 FY27, with new dates landing between September and December 2026. For small domestic brands, the estimated cost of revised PMTA submissions runs $500,000–$750,000 per flavor file. Industry analysts project this will eliminate approximately 30% of currently listed vapor manufacturers from the market.

Meanwhile, states aren’t waiting. They’re building their own regulatory infrastructure, and the direction is clear. The question for distributors isn’t whether this fragmented landscape will get more complex — it’s whether your compliance infrastructure can keep pace with states that are legislating faster than the FDA can authorize.